- Home
- ATNI vs TNGX Comparison
ATNI vs TNGX Comparison
Compare ATNI & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNI
- TNGX
- Stock Information
- Founded
- ATNI 1987
- TNGX 2014
- Country
- ATNI United States
- TNGX United States
- Employees
- ATNI N/A
- TNGX N/A
- Industry
- ATNI Telecommunications Equipment
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- ATNI Telecommunications
- TNGX Health Care
- Exchange
- ATNI Nasdaq
- TNGX Nasdaq
- Market Cap
- ATNI 240.0M
- TNGX 351.2M
- IPO Year
- ATNI 1991
- TNGX N/A
- Fundamental
- Price
- ATNI $18.14
- TNGX $6.01
- Analyst Decision
- ATNI Strong Buy
- TNGX Strong Buy
- Analyst Count
- ATNI 1
- TNGX 6
- Target Price
- ATNI $30.00
- TNGX $12.20
- AVG Volume (30 Days)
- ATNI 49.1K
- TNGX 2.7M
- Earning Date
- ATNI 07-23-2025
- TNGX 08-06-2025
- Dividend Yield
- ATNI 5.32%
- TNGX N/A
- EPS Growth
- ATNI N/A
- TNGX N/A
- EPS
- ATNI N/A
- TNGX N/A
- Revenue
- ATNI $721,575,000.00
- TNGX $40,990,000.00
- Revenue This Year
- ATNI $2.03
- TNGX N/A
- Revenue Next Year
- ATNI $1.59
- TNGX N/A
- P/E Ratio
- ATNI N/A
- TNGX N/A
- Revenue Growth
- ATNI N/A
- TNGX 10.09
- 52 Week Low
- ATNI $13.76
- TNGX $1.03
- 52 Week High
- ATNI $33.72
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- ATNI 64.20
- TNGX 76.36
- Support Level
- ATNI $17.02
- TNGX $5.34
- Resistance Level
- ATNI $18.83
- TNGX $6.40
- Average True Range (ATR)
- ATNI 0.67
- TNGX 0.50
- MACD
- ATNI 0.22
- TNGX -0.02
- Stochastic Oscillator
- ATNI 79.61
- TNGX 84.08
About ATNI ATN International Inc.
ATN International Inc is a telecommunications and utilities company. The company provides digital infrastructure and communications services with a focus on rural and remote markets in the United States, and internationally, including Bermuda and the Caribbean region. Its operating segments comprise U.S. Telecom and International Telecom. The company earns revenue from its International telecommunication segment.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.